1. Introduction {#s0005}
===============

Epidemiological studies have demonstrated that tobacco smoke is a major cause of both cancer and vascular diseases. More than 3800 chemicals are present in tobacco smoke, which may cause oxidative stress via biotransformation or by macrophage activation. In 1954, Richard Doll and Bradford Hill published the first prospective evidence on cigarette smoking and lung cancer [@b0005; @b0010]. In 1962, Framingham investigators published data showing that smoking increased the risk of heart disease [@b0015]. Nevertheless, despite the strong evidence, uncertainty was manufactured and enlarged. This strategy is a common practice to reduce the public health implications from epidemiological findings and was used not only by tobacco companies but also by other industrial arms, including asbestos and lead factories [@b0020]. For almost half a century, the tobacco companies hired scientists to dispute first that smokers were at greater risk of dying of lung cancer; second, the role of tobacco use in heart disease; and finally, the evidence that environmental tobacco smoke increased disease risk in non-smokers [@b0025; @b0030].

The effect of in-utero exposures on health in childhood and later in life is a growing area of research interest, with major public health implications. Children are vulnerable to the adverse effects of environmental tobacco smoke as their lungs and immune system are undergoing further development. The first publications of detrimental health effects of parental smoking on children's respiratory health were published in the early 1970s [@b0035]. Exposure to environmental tobacco smoke in the first 2 years of life has been estimated in some European countries by Pattenden et al. [@b0040] and ranged from 19% in Germany to 70% in Bulgaria.

2. Meta-analytical evidence of early-life effects {#s0010}
=================================================

There is pooled evidence that constituents of cigarette smoke cross the placenta, induce pregnancy complications, reduce intrauterine foetal growth and increase the risk of preterm delivery ([Table 1](#t0005){ref-type="table"}) [@b0045; @b0050]. Meta-analytical evidence has also shown increased risk of respiratory and ear infections [@b0055; @b0060; @b0065], overweight [@b0070]and an increase in blood pressure [@b0075] in early life and/or childhood, suggesting that maternal smoking in pregnancy influences the foetal development of different organ systems. Indeed, low birth weight and preterm delivery are also determinants of health risks later in life, including childhood asthma [@b0080; @b0085]. A cross-sectional study of 11,500 participants of 8--11-year-old children showed that prenatal exposure to cigarette smoke has a stronger effect on childhood asthma compared with postnatal smoke [@b0090]. Prenatal exposure to maternal smoking without subsequent postnatal exposure to environmental tobacco smoke was related to the presence of asthma at school age with an odds ratio (OR) of 1.8 (95%CI: 1.1--2.9) [@b0090].

Parental smoking increases the risk of acute lower respiratory tract diseases in children [@b0060; @b0065]. The pooled estimates showed a higher risk in association with smoking by the mother (OR: 1.56, 95%CI: 1.51--1.62) than with smoking by the father (OR: 1.31, 95%CI: 1.20--1.42) [@b0060]. The higher risk related to the mother's smoking could be explained by the fact that young children usually spend more time with their mother or by the interplay with maternal smoking during pregnancy. In addition to lower respiratory tract infections (OR: 1.51 95%CI: 1.44--1.52), exposure to environmental tobacco smoke has been associated with an increased risk of otitis media (OR: 1.32, 95%CI: 1.14--1.52) [@b0060].

Exposure to prenatal tobacco increases the level of genetic damage in newborns and children. A meta-analysis performed in children exposed to environmental tobacco smoke showed that children and newborns had, respectively, 1.3 and 6.7 times higher levels of haemoglobin adducts compared with non-exposed newborns [@b0095]. Available meta-analytical evidence of an association between in-utero exposure to tobacco smoke from the parents and childhood cancer seems weak. Maternal smoking was estimated as an increased risk of 10% (95%CI: 1.03--1.19) for childhood cancer, yet no significant elevated risk was found for lymphomatic and haematopoietic neoplasm, or for cancer of the central nervous system or kidney cancer ([Table 1](#t0005){ref-type="table"}) [@b0100]. When considering maternal and paternal in-utero exposure to genotoxic compounds, a difference in the mode of action is implied in the direct transplacental effects versus the preconception alterations. Carcinogens in tobacco can induce DNA damage in sperm: male smokers have higher levels of 8-oxo-2-deoxyguanosine in their semen than non-smokers, which may result in oxidative damage to sperm DNA [@b0105; @b0110]. Paternal smoking during conception and acute lymphoblastic leukaemia are related with a pooled odds of 1.15 (CI: 1.06--1.24), paternal exposure during pregnancy is not [@b0100; @b0115]. Furthermore, meta-analytical work suggests an increased risk after paternal exposure to tobacco smoke with childhood non-Hodgkin lymphoma and tumors in the central nervous system [@b0100].

Based on pooled evidence of 25 studies [@b0120], maternal smoking was associated with almost a 4-fold time increase in risk of sudden infant death syndrome. The corresponding risk of paternal smoking with absence of maternal smoking was 1.49 ([Table 1](#t0005){ref-type="table"}). While the effect of smoke exposure in utero seems to be stronger, postnatal environmental tobacco smoke has been found to increase the risk of sudden infant death syndrome even after controlling for prenatal exposure. However, in most cases this is difficult to distinguish as most children that have been exposed in utero are also exposed during their first months of life.

3. Smoking ban and health gains {#s0015}
===============================

The positive effect of smoking cessation suggests a causal association between active smoking and cardiovascular disease [@b0125]. Evidence from observational studies shows a decrease in cardiovascular events in progression of atherosclerosis in those who quit smoking compared with those continuing to smoke cigarettes. Along with this, evidence from cohort studies and ecological evidence on recent smoking bans (introduced by law) consistently shows a rapid decrease in hospitalisation for myocardial infarction (MI). The pooled aggregated data showed that the rate of acute MI hospitalisation in countries that implemented a smoking ban law, decreased 12 months after its implementation, on average by 17% (95%CI: 20--13%) [@b0130]. The rapid decrease in MI after introduction of bans suggests an interplay between chronic and acute processes, including triggers. A trigger can be defined as an external stimulus that produces acute physiological or pathophysiological changes. The idea of the pathophysiological relevance of triggers leading to the onset of acute myocardial infarction (MI) has been proposed [@b0135]. In general, ageing leads to functional and structural abnormalities of the arterial wall, which are amplified by hypertension and atherosclerosis [@b0140]. A vulnerable atherosclerotic plaque might lead to an occlusive thrombus which is more likely to be formed if other factors come into play to narrow homoeostasis and increase vasoconstriction. The role of triggers such as alcohol [@b0145], anger [@b0150; @b0155], physical exertion [@b0155; @b0160]and use of marijuana [@b0165] in the onset of MI is recognised [@b0170].

Recently gained evidence supports the notion that premature birth is also a syndrome which might have trigger components, including ambient temperature and smoking [@b0175; @b0180]. Recent Scottish [@b0180] and Belgian [@b0175] data support reductions in the rate of preterm births after the implementation of smoking bans, whereas no such decrease was evident in the years or months before these bans.

In Belgium, smoke-free legislation was implemented in different phases (in public places and most workplaces in January 2006, in restaurants January 2007, and in bars serving food January 2010). We were able to demonstrate a consistent pattern of changes in preterm delivery with stepwise reductions over the different enforcements. In an analysis using a birth register comprising 606,877 live-births, we observed an immediate change in the risk of spontaneous preterm delivery of −3.13% (95%CI: −4.37% to −1.87%; *P* \< 0.01) on 1st January 2007 (ban on smoking in restaurants), and an annual slope change of −2.65% (−5.11% to −0.13%; *P* = 0.04) after 1st January 2010 (ban on smoking in bars serving food). In 716,941 Scottish newborns, the risk was decreased by 11.72% (95% CI: --15.87 to --7.35) 3 months prior to the introduction of the comprehensive smoking ban in 2006. Similarly to Belgian findings, a study on the impact of the Irish workplace smoking ban on birth weight and preterm birth found a protective effect only on the latter outcome [@b0185]. Although their analysis was limited to a comparison of rates 1 year before and after the ban, they even found an increase in the risk of low birth weight.

The smoking ban studies must be viewed as an investigation of the possible impact of a 'population intervention' rather than an investigation of changes in individual behaviour. It is possible that unmeasured confounders were responsible for the observed changes. Nevertheless, it is hard to conceive of a factor that could change the population risk of preterm births after the introduction of the different successive smoking bans. It is unlikely that our observations could be explained by abrupt changes in therapeutic strategies coinciding with the smoking bans. Nevertheless, the Belgian study collected data on the prescription of atosiban and on cervical cerclage treatment from a social security organisation covering 42% of the population. Atosiban is an inhibitor of oxytocin and vasopressin and is specifically used to halt premature labour. Cervical cerclage is used for the treatment of cervical incompetence, a condition where the cervix has opened slightly and there is a risk of miscarriage.

Given that even a mild reduction in gestational age has been linked to adverse health outcomes in early and later life, these population interventions have important public health implications. Indeed, a Swedish study found that, even among those born late preterm (34--36 weeks), preterm birth was associated with a 31% (13--50%) increase in mortality in young adulthood [@b0190].

4. Molecular epidemiological aspects {#s0020}
====================================

The human placenta forms the interface between foetal and maternal circulation, and by controlling nutrient supply plays a critical role in the regulation of foetal growth and development. Maternal smoking causes perturbations in this utero-placental exchange as it increases the risk of low birth weight [@b0195; @b0200] and preterm delivery [@b0175; @b0205]. The mechanisms underlying these observed effects remain unclear, but emerging data suggest that biochemical, genetic and epigenetic activities respond to and are modified by in-utero tobacco exposure. Nutrients and potential pollutants are metabolised, making the placenta a molecular 'footprint' to which the foetus has been exposed in utero.

Mitochondria are abundant in placental cells, they provide energy for the functioning of this metabolically active organ. Each cell contains approximately 200--2000 mitochondria, carrying between two and ten copies of mitochondrial DNA (mtDNA). Recently, by assessing the relative mtDNA content (a marker of mitochondrial damage and dysfunction), its functioning has been linked to various disease mechanisms [@b0210; @b0215]. The placental mtDNA content has been shown to be very adaptive to environmental insults, including maternal smoking [@b0220] and air pollution [@b0225]. The relative mtDNA content is decreased by 37% (*P* \< 0.02) in placentas of mothers who smoke [@b0220] compared with a decrease of 17.4% (*P* = 0.05) for each 10-μg/m^3^ increase in PM~10~ exposure during the third trimester of pregnancy [@b0225].

Important questions remain concerning how mitochondrial biogenesis and maintenance are regulated as a response to tobacco exposures, and how these relate to placental functioning. An attractive link between adverse insults and altered foetal development is gene regulation. Maternal smoking during pregnancy can lead to changed placental gene expression levels, which is epigenetically regulated by DNA methylation, histone modifications or non-coding RNAs. Epigenetic changes can occur throughout the course of life as a result of environmental conditions. Much of the epigenome is already established in germ cells and embryos as it appears to be particularly important for the regulation of embryonic growth and placental development [@b0230]. Recently, studies investigating cord blood and placental tissue showed that the epigenetic system is sensitive to tobacco exposure in utero. Global DNA methylation levels in cord blood is lower among newborns with smoking mothers (mean = 15.04%; 95%CI: 8.4--21.7) compared with second-hand smokers (21.1%; 95%CI: 16.6, --25.5) and their non-smoking counterparts (mean = 29.2%; 95%CI: 20.1--38.1) [@b0235]. An epigenome-wide methylation study in cord blood of newborns exposed to tobacco smoke during pregnancy showed that genes that play an important role in detoxifying components of tobacco smoke (*AHRR* and *CYP1A1*) are differentially methylated [@b0240]. Accordingly, Suter and colleagues reported site-specific changes in DNA methylation of the *CYP1A1* promoter, and this hypomethylation correlated with an increase in *CYP1A1* gene expression in the placenta [@b0245]. They showed in an epigenome-wide methylation study on placental tissue that methylation levels of 623 genes are deregulated in a CpG site-specific manner [@b0250].

Despite a limited number of (epi)genomic studies in cord blood and placental tissue, we are getting a better picture of how maternal tobacco smoke can alter placental functioning and contribute to adverse pregnancy outcomes. Therefore the potential health consequences of changes in mitochondrial functioning, gene expression and epigenetics in early life should be further elucidated.

5. Multiple choice questions {#s0025}
============================

5.1. Question 1 {#s0030}
---------------

Does exposure to smoking only during the pregnancy increase the prevalence of asthma in the child, and does the risk of asthma depend on parental and/or maternal smoking?A.No, prenatal smoking does not have a higher risk than postnatal exposure; maternal as well as paternal smoking increase the risk of asthma.B.Yes, prenatal more than postnatal exposure increases the risk of asthma; however, only maternal smoking increases the risk of asthma.C.No, prenatal smoking does not have a higher risk than postnatal exposure, only maternal smoking increases the risk of asthma.D.Yes, prenatal more than postnatal exposure increases the risk of asthma, and maternal as well as paternal smoking increase the risk of asthma.E.Prenatal exposure is equally important as postnatal exposure for increasing the risk of asthma, and maternal as well as paternal exposure increase the risk of asthma.

5.2. Question 2 {#s0035}
---------------

Environmental insults during the in-utero period could potentially affect the unborn foetus. The question remains whether the foetus is affected in a direct manner or indirectly by adaptations in placental functioning or other protective barriers. What is *the best possible way* to explore whether these effects are transmitted directly or indirectly?A.By assessing pollutants and/or metabolites in maternal matrices, cord blood and placental tissue to measure the effective dose to which the matrices are subjected, in combination with molecular analysis of biomarkers of effect in the corresponding matrices.B.By assessing environmental exposure through questionnaires in combination with molecular analysis of biomarkers of effects in cord blood, placental tissue and maternal matrices.C.A prospective study, where a 'baseline' analysis of molecular markers in maternal matrices, together with biomarkers of effect in placental tissue and cord blood during pregnancy, can provide a better picture of molecular changes during pregnancy.D.A retrospective study to see whether a difference in molecular measurement is seen in children who develop adverse health outcomes, including low birth weight, and see how this relates to in-utero exposure.E.Combination of A and B.F.Combination of B and D.G.Combination of A, B and D.

5.3. Question 3 {#s0040}
---------------

Smoking ban policies have been studied.A.There is no consistency in these studies, and risk reductions differ largely between countries.B.As the intervention is population-based, the interpretation should be at the group level.C.Epidemiological studies on smoking ban legislation reflect the effect of the reduction of exposure at work, in restaurants etc.D.Epidemiological studies on smoking ban legislation reflect the population reduction, including the societal effects of making smoking less acceptable after introduction of the ban.
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Meta-analytical evidence of early-life exposure to cigarette smoke.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Disease                                                                        Author/Year (population)                                                     Design                 N articles   N                       Pooled Estimate
  ------------------------------------------------------------------------------ ---------------------------------------------------------------------------- ---------------------- ------------ ----------------------- ------------------------------------------------------------------------------------------------------------
  Placenta previa                                                                Castles et al. [@b0045]\                                                     Case--control\         6            50.695 Patients         1.58 (1.04--2.12)[a](#tblfn1){ref-type="table-fn"}
                                                                                 (North America, Western Europe)                                              Cohort                                                      

  Abruptio placenta                                                                                                                                                                  8            57.302                  1.62 (1.46--1.77)[a](#tblfn1){ref-type="table-fn"}

  Ectopic pregnancy                                                                                                                                                                  9            10.632                  1.77 (1.31--2.22)[a](#tblfn1){ref-type="table-fn"}

  Preterm PROM[c](#tblfn3){ref-type="table-fn"}                                                                                                                                      6            34.668                  1.7 (1.18--2.25)[a](#tblfn1){ref-type="table-fn"}

  Pre-eclampsia                                                                                                                                                                      5            4.451                   0.51 (0.38--0.64)[a](#tblfn1){ref-type="table-fn"}

  Preterm delivery\                                                              Shah et al. [@b0050] (Europe, North America)                                 Case--control          20           Cases: \>100.000        1.27 (1.21--1.33)[a](#tblfn1){ref-type="table-fn"}
  (\>32 weeks but \<37 weeks of gestation)                                                                                                                                                                                

  0-10 Cig/Day: 1.25 (1.12--1.38)[a](#tblfn1){ref-type="table-fn"}                                                                                                                                                        

  11-20 Cig/Day: 1.38 (1.23--1.55)[a](#tblfn1){ref-type="table-fn"}                                                                                                                                                       

  \>1 Pack/Day: 1.31 (1.19--1.45)[a](#tblfn1){ref-type="table-fn"}                                                                                                                                                        

  Acute lymphoblastic Leukaemia (Childhood)                                      Boffeta et al. [@b0100] (Europe, North America)                              Case--control          4            Primary Not Given       Paternal smoking during pregnancy1.17 (0.96--1.42)[b](#tblfn2){ref-type="table-fn"}

                                                                                 Milne et al. [@b0115] (Europe, North America, Australia)                                            11           Cases: 1994             Paternal smoking around the time of conception1.15 (1.06--1.24)[a](#tblfn1){ref-type="table-fn"}

  Acute otitis media                                                             Moritsugu et al. [@b0060] (Europe, North America, Australia, Asia, Africa)                          3            Primary Not Given       Smoking by Either Parent0.99 (0.70--1.40)[a](#tblfn1){ref-type="table-fn"}

  Asthma                                                                         Moritsugu et al. [@b0060] (Europe, North America, Australia, Asia, Africa)                          31           Primary Not Given       Asthma

  Smoking by Either Parent: 1.23 (1.14--1.33)[a](#tblfn1){ref-type="table-fn"}                                                                                                                                            

  Smoking by Both Parents: 1.42 (1.30--1.56)[a](#tblfn1){ref-type="table-fn"}                                                                                                                                             

  Maternal Smoking: 1.33 (1.24--1.43)[a](#tblfn1){ref-type="table-fn"}                                                                                                                                                    

  Paternal Smoking: 1.07 (0.97--1.18)[a](#tblfn1){ref-type="table-fn"}                                                                                                                                                    

  Bladder cancer                                                                 Van Hemelrijck et al. [@b0255] (Asia, Europe, North America)                 Case--controlCohort    8            ∼223.000 Participants   Childhood Exposure1.19 (0.88--1.62)[b](#tblfn2){ref-type="table-fn"}

  Blood pressure                                                                 Brion et al. [@b0075] (Primary not given)                                    Cohort                 9            16.690 Participants     Maternal Smoking During Pregnancy\
                                                                                                                                                                                                                          Systolic Blood Pressure:0.67 mmHg (0.31 to 1.04)

  Breast cancer                                                                  Pirie et al. [@b0260] (Asia, Europe, North America)                          Case--controlCohort    25           ∼220.000 Participants   Childhood Exposure: 0.98 (0.88--1.08)[b](#tblfn2){ref-type="table-fn"}

  Childhood cancer (overall)                                                     Boffeta et al. [@b0100] (Europe, North America)                              Case--control Cohort   12           900 participants\       Maternal smoking during pregnancy1.10 (1.03--1.19)[b](#tblfn2){ref-type="table-fn"}
                                                                                                                                                                                                  6351 cases\             
                                                                                                                                                                                                  6253 controls           

  Cough                                                                          Moritsugu et al. [@b0060] (Europe, North America, Australia, Asia, Africa)                          39           Primary not given       Cough

  Smoking by either parent: 1.35 (1.27--1.43)[a](#tblfn1){ref-type="table-fn"}                                                                                                                                            

  Smoking by both parents: 1.64 (1.48--1.81)[b](#tblfn2){ref-type="table-fn"}                                                                                                                                             

  Maternal smoking: 1.34 (1.17--1.54)[a](#tblfn1){ref-type="table-fn"}                                                                                                                                                    

  Paternal smoking: 1.22 (1.12--1.32)[a](#tblfn1){ref-type="table-fn"}                                                                                                                                                    

  Cancer of the nervous system (childhood)                                       Boffeta et al. [@b0100] (Europe, North America)                              Case--control          12           Primary not given       Maternal smoking during the pregnancy\
                                                                                                                                                                                                                          1.04 (0.92--1.18)[b](#tblfn2){ref-type="table-fn"}

                                                                                                                                                              Case--control          10           1627 cases\             Paternal smoking during pregnancy\
                                                                                                                                                                                                  2974 controls           1.22 (1.05--140)[b](#tblfn2){ref-type="table-fn"}

  Genetic damage in children                                                     Neri et al. [@b0095]\                                                        Case--control\         6            Primary not given       HB adducts\
                                                                                 (Australia, Europe, USA, South America)                                      Cohort                                                      Children exposed to environmental tobacco\
                                                                                                                                                                                                                          smoke: 1.38 (0.98--1.96)

                                                                                                                                                                                     5                                    Prenatal Exposure: 6.67 (2.56--17.24)\
                                                                                                                                                                                                                          SCE[e](#tblfn5){ref-type="table-fn"}:prenatal exposure: 1.02 (0.94--1.10)[d](#tblfn4){ref-type="table-fn"}

  Lower respiratory illnesses                                                    Moritsugu et al. [@b0060] (Europe, North America, Australia, Asia, Africa)   Case--control\         38           Primary not given       Lower respiratory illnesses
                                                                                                                                                              Cohort                                                      

  Smoking by either parent: 1.51 (1.44--1.59)[a](#tblfn1){ref-type="table-fn"}                                                                                                                                            

  Maternal smoking: 1.56 (1.51--1.62)[a](#tblfn1){ref-type="table-fn"}                                                                                                                                                    

  Paternal smoking: 1.31 (1.20--1.42)[a](#tblfn1){ref-type="table-fn"}                                                                                                                                                    

  Lower respiratory tract infection                                              Li et al. [@b0055] (Asia, Europe, North America)                             Case--control Cohort   13           32,945 cases            Hospitalisation for respiratory illness\
                                                                                                                                                                                                                          1.93 (1.66--2.25)[a](#tblfn1){ref-type="table-fn"}\
                                                                                                                                                                                                                          Serious infections0--2 years: 1.71 (1.33--2.20)[a](#tblfn1){ref-type="table-fn"}\
                                                                                                                                                                                                                          3-6 years: 1.25 (0.88--1.78)[a](#tblfn1){ref-type="table-fn"}

  Lymphatic and haematopoietic\                                                  Boffeta et al. [@b0100]\                                                     Case--control          9            Cases: 3610\            Maternal smoking during pregnancy 1.03 (0.90--1.17)
  Neoplasm (childhood)                                                           (Europe, North America)                                                                                          Controls: 5054          

  Kidney cancer (childhood)                                                      Boffeta et a. [@b0100]\                                                      Case--control          5            Cases: 442\             Maternal smoking during pregnancy\
                                                                                 (Europe, North America)                                                                                          Controls: 2536          0.95 (0.76--1.19)

  Middle ear effusion                                                            Moritsugu et al. [@b0060]\                                                                          6            Primary not given       Middle ear effusion
                                                                                 (Europe, North America, Australia, Asia, Africa)                                                                                         

  Smoking by either parent: 1.20 (0.90--1.60)[a](#tblfn1){ref-type="table-fn"}                                                                                                                                            

  Maternal smoking: 1.84 (1.54--2.20)[a](#tblfn1){ref-type="table-fn"}                                                                                                                                                    

  Paternal smoking: 1.49 (1.13--1.96)[a](#tblfn1){ref-type="table-fn"}                                                                                                                                                    

  Non-Hodgkin lymphoma (childhood)                                               Boffeta et al. [@b0100]\                                                     Case--control          4            Primary not given       Paternal smoking during the pregnancy\
                                                                                 (Europe, North America)                                                                                                                  2.08 (1.08--3.98)[b](#tblfn2){ref-type="table-fn"}

  Overweight[f](#tblfn6){ref-type="table-fn"}                                    Oken et al. [@b0160]\                                                        Cohort                 14           84,563 Participants     Maternal smoking during pregnancy\
                                                                                 (Australia, Europe, North America)                                                                                                       1.50 (1.36--1.65)[a](#tblfn1){ref-type="table-fn"}

  Recurrent otitis media                                                         Moritsugu et al. [@b0060]\                                                                          9            Primary not given       Recurrent otitis media
                                                                                 (Europe, North America, Australia, Asia, Africa)                                                                                         

  Smoking by either parent: 1.32 (1.14--1.52)[a](#tblfn1){ref-type="table-fn"}                                                                                                                                            

  Maternal smoking: 1.37 (1.19--1.59)[a](#tblfn1){ref-type="table-fn"}                                                                                                                                                    

  Paternal smoking: 0.90 (0.70--1.15)[a](#tblfn1){ref-type="table-fn"}                                                                                                                                                    

  Respiratory tract infections                                                   Peat et al. [@b0065] (Asia, Australia, Chili, Europe, New Zealand, USA)      Case--control Cohort   14           Primary not given       Parental smoking

  Hospitalisation for respiratory illness: 2[a](#tblfn1){ref-type="table-fn"}                                                                                                                                             

  Lower respiratory tract infection: 1.7[a](#tblfn1){ref-type="table-fn"}                                                                                                                                                 

  Early respiratory illness: 1.6[a](#tblfn1){ref-type="table-fn"}                                                                                                                                                         

  Sudden infant death syndrome\                                                  Mitchell et al. [@b0120]\                                                    Case--control\         24           Cases: 15,694\          Maternal smoking during pregnancy\
  (after prone-sleep-position intervention programs)                             (Europe, New Zealand, US)                                                    Cohort                              Controls: 3,592,021\    3.93 (3.78--4.08)[b](#tblfn2){ref-type="table-fn"}\
                                                                                                                                                                                                  Cases: 719\             Paternal smoking, mother does not smoke\
                                                                                                                                                                                                  Controls: 4885          1.49 (1.25--1.77)[b](#tblfn2){ref-type="table-fn"}

  Wheeze                                                                         Moritsugu et al. [@b0060] (Europe, North America, Australia, Asia, Africa)                          45                                   Wheeze

  Smoking by either parent: 1.26 (1.20--1.33)[a](#tblfn1){ref-type="table-fn"}                                                                                                                                            

  Smoking by both parents: 1.41 (1.23--1.63)[a](#tblfn1){ref-type="table-fn"}                                                                                                                                             

  Maternal smoking: 1.28 (1.21--1.35)[a](#tblfn1){ref-type="table-fn"}                                                                                                                                                    

  Paternal smoking: 1.22 (1.12--1.32)[a](#tblfn1){ref-type="table-fn"}                                                                                                                                                    
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Odds ratio.

Relative risk.

PROM, premature rupture of membranes is a rupture (breaking open) of the membranes (amniotic sac) before labour begins. If PROM occurs before 37 weeks of pregnancy, it is called preterm premature rupture of membranes (PPROM).

MR is a point estimate of the relative effect of the exposure on biomarker level detected in each study taking the value 1 when there is no effect, values \>1 when exposure is associated with a decreased level of the investigated biomarker.

SCE: sister chromatid exchange is the exchange of genetic material between two identical sister chromatids. The reason for the SCE is not known but it is required and used for mutagenic testing of many products. Four to five sister chromatid exchanges are in the normal distribution, 14--100 exchanges are not normal and present a danger to the organism.

Primary analysis of overweight has been chosen, defined as BMI ⩾85th percentile or ⩾90th percentile for age and sex.
